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A new pathway for mitogen-dependent Cdk2 regulation
uncovered in p27Kip1-deficient cells
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Background: The ability of cyclin-dependent kinases (CDKs) to promote cell
proliferation is opposed by cyclin-dependent kinase inhibitors (CKIs), proteins
that bind tightly to cyclin–CDK complexes and block the phosphorylation of
exogenous substrates. Mice with targeted CKI gene deletions have only subtle
proliferative abnormalities, however, and cells prepared from these mice seem
remarkably normal when grown in vitro. One explanation may be the operation
of compensatory pathways that control CDK activity and cell proliferation when
normal pathways are inactivated. We have used mice lacking the CKIs p21Cip1
and p27Kip1 to investigate this issue, specifically with respect to CDK regulation
by mitogens.
Results: We show that p27 is the major inhibitor of Cdk2 activity in mitogen-
starved wild-type murine embryonic fibroblasts (MEFs). Nevertheless,
inactivation of the cyclin E–Cdk2 complex in response to mitogen starvation
occurs normally in MEFs that have a homozygous deletion of the p27 gene.
Moreover, CDK regulation by mitogens is also not affected by the absence of
both p27 and p21. A titratable Cdk2 inhibitor compensates for the absence of
both CKIs, and we identify this inhibitor as p130, a protein related to the
retinoblastoma gene product Rb. Thus, cyclin E–Cdk2 kinase activity cannot be
inhibited by mitogen starvation of MEFs that lack both p27 and p130. In
addition, cell types that naturally express low amounts of p130, such as 
T lymphocytes, are completely dependent on p27 for regulation of the 
cyclin E–Cdk2 complex by mitogens.
Conclusions: Inhibition of Cdk2 activity in mitogen-starved fibroblasts is usually
performed by the CKI p27, and to a minor extent by p21. Remarkably p130, a
protein in the Rb family that is not related to either p21 or p27, will directly
substitute for the CKIs and restore normal CDK regulation by mitogens in cells
lacking both p27 and p21. This compensatory pathway may be important in
settings in which CKIs are not expressed at standard levels, as is the case in
many human tumors.
Background
Cyclin-dependent kinases (CDKs) are not only essential
for the cell division cycle but are also the targets of signals
that regulate cell proliferation. This concept was first
established genetically in fission yeast through studies of
the relationship between cell size and cell division [1,2]
and in budding yeast through studies of the cell cycle
arrest induced by mating pheromone [3–6]. Other cues that
modulate cell division have also been explained in terms of
CDK regulation. The ‘DNA-damage checkpoint’ causes
CDK inactivation [7–9] when the cell cycle is paused to
allow completion of repair to damaged DNA  and
decreased CDK activity also accompanies exit from the
cell cycle after mitogen starvation [10–12], after loss of
integrin-dependent anchorage to a substratum [13–15], and
during cellular differentiation [11,16–18]. In many cases,
cells can be engineered to express CDK activity that is not
sensitive to the anti-proliferative signal and this at least
partially abrogates the cell cycle response as well, indicat-
ing that CDK downregulation is essential [13,16,19–22].
Thus, conditions that stop the cell division cycle often ini-
tiate pathways that lead to inactivation of CDKs.
CDK activity can be controlled by protein–protein interac-
tions and by phosphorylation, and both of these general
mechanisms have been implicated in CDK regulation in
response to proliferative signals [23]. CDKs are positively
regulated through their interactions with cyclins, and for-
mation of the cyclin–CDK holoenzyme is upregulated by
proliferative signals, such as serum mitogens [24], cell
anchorage [25], and extracellular nutrients [26–28]. In
some cases holoenzyme formation is accomplished by
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modulating cyclin abundance through transcriptional
[24,28–31] and translational pathways [25,27,32], and in
others by controlling the assembly or the stability of the
cyclin–CDK complex [33]. Knockout mice have been
used to further refine this idea and to show that specific
signaling pathways are linked to the regulation of individ-
ual cyclins. Thus, granulosa cell mitogenesis in response
to follicle-stimulating hormone requires cyclin D2, and
steroid-hormone-induced proliferation of the mammary
epithelium requires upregulation of cyclin D1 [34,35].
Conversely, inhibition of CDK activity in response to anti-
mitogenic signals can also be mediated by phosphoryla-
tion of residues within the ATP-binding pocket of the
enzyme and by association of the CDK with inhibitory
subunits. For instance, inhibitory phosphorylation of
CDKs occurs as part of the ‘budding checkpoint’ pathway
in Saccharomyces cerevisiae [36,37], and after DNA damage
in a variety of organisms [8,21,38–41]. Binding of CDKs to
inhibitory subunits called cyclin-dependent kinase
inhibitors or CKIs [42] has been observed in response to
contact inhibition, transforming growth factor β (TGF-β),
mitogen starvation, loss of anchorage, cell senescence,
DNA damage, and cell differentiation [42]. Experiments
using immortalized mammalian cell lines have generally
led to the conclusion that CKIs are necessary for these
antimitogenic signals to stop the cell cycle. In mitogen-
starved, quiescent murine and human cell lines p27 is
upregulated and quantitatively associated with the cyclin
E–Cdk2 complex. Antisense inhibition of p27 expression
renders Cdk2 activity mitogen-independent, and delays
cell cycle arrest after removal of serum mitogens [43,44].
Another example is targeted deletion of the gene encod-
ing p21 from a colon carcinoma cell line, which abrogates
the normal cell cycle arrest induced by DNA damage [45].
Mice with targeted deletions of specific CKI genes
provide a different approach towards understanding the
role of CKIs in controlling cell proliferation. These mice,
and cells isolated from them, display subtle cell cycle
abnormalities that are consistent with a role for the CKIs
in regulating CDKs and cell proliferation. Mice that lack
p21 have a partially defective cell cycle response to DNA
damage [46–48], and keratinocytes isolated from these
mice turn on differentiation markers in vitro more slowly
than do wild-type cells [49]. Cells from p27-deficient mice
show partially diminished mitogen-dependence both in
vitro and in vivo [50–52]; this results in organ hypercellu-
larity and mice that grow larger than normal. The p57Kip2-
deficient mice exhibit delayed or moderately impaired
differentiation of cells in the chondrocyte and muscle lin-
eages [53,54]. In none of these CKI-deficient mice,
however, are there gross defects in cell differentiation,
anchorage-dependence, contact inhibition, or responsive-
ness to TGF-β. This raises the question of whether there
is functional redundancy among the CKIs or whether
there might be other pathways for controlling cell cycle
proteins that become operative when normal regulators
are absent. Evidence for redundancy is provided by the
synergistic enhancement of cell proliferation in the lens of
mice lacking both p27 and p57 [55]. Nevertheless, even
loss of both p27 and p57 had remarkably tissue-limited
effects. We have pursued these questions by using geneti-
cally engineered mice lacking one or more CKIs to study
CDK regulation by serum mitogens. We find that associa-
tion with p27 is likely to be the primary means by which
CDKs are inactivated in normal mitogen-starved cells, but
unexpectedly that the Rb-related protein p130 can com-
pensate for the absence of p27 and restore CDK regula-
tion and mitogen-responsiveness to p27-deficient cells.
Results
Inactivation of cyclin E–Cdk2 in mitogen-starved cells
Murine embryonic fibroblasts (MEFs) were isolated from
embryonic day 12 wild-type mice and maintained accord-
ing to the 3T3 protocol. Wild-type MEFs underwent crisis
approximately at passage 10 to 15, after which immortal-
ized cell lines could be established. Cell cycle regulation
was highly variable among different established lines, pre-
sumably reflecting the particular combination of mutagenic
events that accompanied immortalization. Consequently
the studies described below were performed exclusively
on early passage (pre-crisis) cells, which behaved much
more uniformly than immortalized cells.
Early passage ‘primary’ wild-type MEFs and MEFs con-
taining a homozygous targeted deletion of the p27 gene
(passage 2–4) [50] were placed into medium containing
0.1% serum for 24 hours and analyzed by flow cytometry.
MEFs of both genotypes efficiently underwent growth
arrest at the G0–G1 phase boundary following serum star-
vation (Figure 1a). The expression of neither the gene
encoding cyclin E (Figure 1b) nor that encoding Cdk2
(data not shown) was significantly decreased in quiescent
MEFs, and the abundance of the cyclin E–Cdk2 complex
closely approximated that in proliferating cells (Figure 1b);
nevertheless, in both p27+/+ and p27–/– MEFs cyclin
E–Cdk2 complexes were catalytically active only in prolif-
erating cells (Figure 1b). Cyclin E and Cdk2 were both
located in the nucleus in quiescent MEFs (data not
shown). The mechanism by which Cdk2 activity is down-
regulated following mitogen starvation in wild-type and
p27-null MEFs is the subject of this study.
Regulation of cyclin E–Cdk2 by the p27 and p21 CKIs
In primary wild-type MEFs the CKI p27 was induced by
mitogen starvation (Figure 1c) whereas the level of p21
slightly declined (Figure 1d). Significant amounts of p57
were not detected (data not shown). The association of
cyclin E and Cdk2 with p21 and p27 was measured by
immunoprecipitation and by western blotting (Figure 1c,d).
In wild-type MEFs the association of cyclin E and Cdk2
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with p27 greatly increased in serum-starved cells, whereas
the association of cyclin E–Cdk2 with p21 was essentially
unchanged. Immunodepletion of p27 from lysates of quies-
cent cells removed at least 90% of the cyclin E–Cdk2 com-
plexes, whereas most cyclin E–Cdk2 complexes in
proliferating cells were not associated with p27 (data not
shown). Together, these studies suggest that induction of
p27 and the binding of p27 to cyclin E–Cdk2 results in
Cdk2 inactivation in serum- starved MEFs, as previously
observed in established murine cell lines [44]. The data also
allow for the possibility that p21 participates in Cdk2 inacti-
vation in mitogen- starved cells, but its contribution would
be relatively minor.
Even though p27 is the major inhibitor of cyclin E–Cdk2 in
quiescent wild-type MEFs, cyclin E–Cdk2 complexes iso-
lated from quiescent p27–/– MEFs were nonetheless cat-
alytically inactive (Figure 1b). Hence, other inhibitors must
substitute for p27. Whatever the compensatory pathway is,
it does not solely involve p21, because p21 levels were not
elevated in p27–/– cells when compared with wild-type
MEFs, nor was there a change in the amount of p21 bound
to cyclin E (Figure 1d). To further substantiate this conclu-
sion MEFs were prepared from mice containing homozy-
gous deletions of both the p21 and p27 genes. MEFs taken
from p21–/–p27–/– doubleknockout mice exited from the cell
cycle following serum starvation as effectively as did wild-
type cells (Figure 1e). When compared with proliferating
cells, serum-starved p21–/–p27–/– MEFs had a slight
decrease in the levels of cyclin E protein. Nevertheless, the
amount of Cdk2 that associated with cyclin E was equiva-
lent between proliferating and mitogen-deprived cells, and
both the Thr160- phosphorylated and unphosphorylated
forms of Cdk2 were present in the complex (data not
shown). The cyclin E–Cdk2 complex was catalytically inac-
tive in serum- starved p21–/–p27–/– cells, however, and
therefore was mitogen-responsive despite the absence of
both p21 and p27 (Figure 1e).
No evidence for altered Cdk2 phosphorylation in 
p27-null MEFs 
Inhibitory phosphorylation of Cdk2 on Thr14 and/or Tyr15
might have accounted for its downregulation in quiescent
p27–/– cells. To test this hypothesis, p27–/– cells were trans-
fected with a mutant version of Cdk2 (Cdk2-AF) in which
both Thr14 and Tyr15 were replaced with nonphosphory-
latable residues (Thr14 to alanine and Tyr15 to phenylala-
nine). Cells were transfected with plasmids encoding
Myc-epitope-tagged cyclin E (Myc–cycE) and haemagglu-
tinin(HA)-epitope-tagged Cdk2-AF (HA–Cdk2-AF), and
then serum-starved for 24 hours. The catalytic activity of
the cyclin E–Cdk2-AF complex was measured following
immunoprecipitation using antibodies specific for human
cyclin E (Figure 2) or HA (data not shown) epitopes.
Figure 2a shows that cyclin E–Cdk2-AF complexes 
were inactive in serum-starved p27–/– and p27+/+ MEFs,
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Figure 1
Regulation of cyclin E–Cdk2 in wild-type and p27–/– MEFs. (a) Wild-
type (p27+/+) and p27–/– proliferating MEFs (high serum) were placed in
0.1% serum for 24 h (low serum) and subsequently analyzed by flow
cytometry. (b) Extracts were prepared from proliferating (high serum, Hi)
or serum-starved (low serum, Lo) MEFs and were immunoblotted with
cyclin-E-specific antiserum (left). These same extracts were
immunoprecipitated with cyclin E antibody. The amount of Cdk2 bound
to cyclin E was determined by western blot (middle); Cdk2* designates
the phosphorylated, active form of Cdk2. The amount of cyclin-E-
associated histone H1 kinase activity was measured (right). In this
experiment, and in all other cyclin E immunoprecipitations, excess anti-
cyclin E antibody was used and it was confirmed that cyclin E was
quantitatively immunoprecipitated from the cell extracts. (c) The amount
of p27 expressed in proliferating and serum-starved MEFs was
determined by western blot. The top panel is a p27 western blot of the
whole-cell extract, and the bottom panel is a western blot of cyclin E
immunoprecipitates. (d) The amount of p21 expressed in proliferating
and serum-starved MEFs was determined by western blot (left). The
amount of p21 bound to cyclin E was measured in the same samples
(right). (e) Flow cytometry  was performed on proliferating (high serum)
or serum-starved (low serum) primary p27–/–p21–/– MEFs. Cyclin E was
immunoprecipitated from these cells and the amount of associated
kinase activity measured using histone H1 as a substrate (right).
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demonstrating that phosphorylation at Thr14 or Tyr15 is
not necessary for inhibiting cyclin E–Cdk2 kinase activity.
An alternative explanation for inactivation of the cyclin
E–Cdk2 complex in p27–/– cells was downregulation of the
CDK activating kinase (CAK) and therefore a lack of
phosphorylation at Thr160. To address this issue, we
tested whether recombinant CAK could activate cyclin
E–Cdk2-AF complexes that had been immunoprecipi-
tated from serum-starved p27–/– cells (Figure 2). As a
control we used immunoprecipitated, inactive, recombi-
nant cyclin E–Cdk2 complexes that had been assembled
in vitro by mixing extracts of insect cells that had been
separately infected with cyclin E and Cdk2 baculoviral
expression vectors. In a side-by-side experiment, CAK did
activate recombinant, inactive cyclin E–Cdk2 complexes
but did not activate cyclin E–Cdk2 complexes isolated
from serum-deprived p27–/– MEFs. This experiment was
performed within the linear range of the assay, and an
equal amount of cyclin E–Cdk2-AF and recombinant
cyclin E–Cdk2 complexes were used. In sum, the inacti-
vation of cyclin E–Cdk2 complexes in mitogen-deprived
p27–/– MEFs could not be explained by either the pres-
ence of an inactivating phosphorylation at Thr14 and
Tyr15 or the absence of CAK.
A titratable Cdk2 inhibitor in p27–/– cells
The above experiments indicated that none of the com-
monly studied mechanisms was responsible for downregu-
lating Cdk2 in serum-starved p27–/– cells. To determine
whether or not a stoichiometric inhibitor of cyclin E–Cdk2
might compensate for the absence of p27, we examined
the effect of increasing the amount of cyclin E–Cdk2 com-
plexes in quiescent cells. We established stable cell lines
that overexpressed human cyclin E about threefold to
fourfold compared with the endogenous murine protein
(Figure 3a, and data not shown). Control cell lines
infected with the LXSH viral vector alone were also estab-
lished. Overexpression of cyclin E did not block the exit
from the cell cycle in serum-starved wild-type, or p27–/–
MEFs (Table 1). In contrast, overexpression of cyclin E in
cells lacking both p21 and p27 stimulated cells to remain
in the cell cycle for at least 24 hours following serum
deprivation (Table 1). Moreover, p21–/–p27–/– MEFs had
increased levels of cyclin-E-associated kinase activity in
both proliferating and serum-starved cells when compared
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Figure 2
Phosphorylation of Cdk2 does not regulate its
activity in quiescent p27–/– MEFs. The p27–/–
and p27+/+ MEFs were transfected with Myc-
epitope-tagged human cyclin E and an HA-
epitope-tagged Cdk2 mutant (Cdk2-AF) that
replaced Thr14 with an alanine and Tyr15
with phenylalanine. Transfected cells were re-
fed with medium containing 10% serum (Hi)
or 0.1% serum (Lo) and incubated for 24 h.
(a) Immunoprecipitations were performed
using an anti-HA antibody and the
immunoprecipitates assayed for kinase activity
against histone H1. (b) Immunoprecipitations
were performed as in (a) except that
antibodies that recognize the transfected
cyclin E were used instead of anti-HA. The
immunoprecipitations were divided and half of
the cyclin E immunoprecipitate was left
untreated and half was treated with active
recombinant CAK. Control experiments were
done to adjust the amount of CAK in order to
ensure that it was not a limiting component of
the reactions (data not shown). The titration of
the recombinant cyclin E–Cdk2 complexes
was adjusted so that the amount of cyclin
E–Cdk2 immunoprecipitated from the cell
extract was at the midpoint of the titration (data
not shown). Histone H1 kinase assays were
performed on cyclin E immunoprecipitates
(lanes 1–2) or on CAK-treated samples
(lanes 3–4). For comparison, a titration (1–5 µl)
of inactive recombinant cyclin E–Cdk2 (HA-
tagged) complexes were immunoprecipitated
with human-specific anti-cyclin E antibodies
and incubated with a fixed amount of active
CAK. Histone H1 kinase assays were
performed on CAK-activated recombinant
cyclin E–Cdk2 complexes (lanes 6–10) and
control untreated immunoprecipitated cyclin
E–Cdk2 complexes (lane 5).
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Figure 3
A titratable inhibitor of cyclin E–Cdk2 in p21–/–p27–/– MEFs.
(a) Western blots were performed using antibodies that specifically
recognize human cyclin E on proliferating (high serum, Hi) and serum-
starved (low serum, Lo) MEFs of the indicated genotypes that had
been infected with a retrovirus expressing human cyclin E
(LXSH–cyclin E) or empty retroviral vector (LXSH). (b) Histone H1
kinase assays were performed on human-specific cyclin E
immunoprecipitations from the cells characterized in (a).
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with wild-type or p27–/– cells (Figure 3b). These effects
are not due to differences in the amount of exogenous
cyclin E expression between cells of various genotypes
(Figure 3a). In the absence of both p27 and p21, therefore,
overexpression of cyclin E results in constitutive cyclin-E-
associated kinase activity and in dysregulation of serum
responsiveness. These results showed that the inhibition
of Cdk2 kinase activity in serum-starved p27-deficient
cells is due to a titratable inhibitor. This inhibitor was not
heat stable (data not shown).
Inhibition of Cdk2 by p130
Previous work has shown that binding of the Rb-related
protein p107 to the cyclin E–Cdk2 complex inhibits the
phosphorylation of exogenous substrates [15]. Although
p107 is expressed primarily in proliferating cells, another
Rb family member, p130, is induced in quiescent cells
[56,57]. Moreover, recent work has shown that p130, like
p107, can inhibit CDKs in vitro [58], but neither p130 nor
p107 has previously been implicated in the physiological
regulation of CDK catalytic activity in vivo. MEFs, like
other previously studied cell types, induce p130 when
starved of serum mitogens (Figure 4a; note that the upper
band is non-specific as it is also present in p130-null
MEFs; see later). In wild-type cells only a small fraction of
cyclin E is bound to p130 (Figure 4a), probably because
cyclin E is instead tightly bound to p27 in quiescent cells
and to p21 in proliferating cells. In p27–/– cells the associa-
tion of p130 with both cyclin E and Cdk2 is altered. First,
a substantial amount of p130 is bound to cyclin E specifi-
cally in quiescent p27–/– cells (Figure 4a). Moreover,
immunodepletion experiments show that in quiescent
cells lacking both p27 and p21 more than 80% of cyclin
E–Cdk2 complexes are bound to p130 (data not shown).
Second, the association of p130 with Cdk2 is increased in
both dividing and non-dividing cells (data not shown). In
dividing cells this presumably represents association of
p130 with a fraction of the cyclin A–Cdk2 complexes,
which are much more abundant than cyclin E–Cdk2. 
We also showed that the binding of p130 to cyclin
E–Cdk2 inhibits its catalytic activity both in vivo and in
vitro. Insect cells were co-infected with baculoviral vectors
expressing cyclin E and Cdk2, together with an increasing
amount of a baculoviral vector expressing p130. Cyclin
E–Cdk2 complexes were then immunoprecipitated and
their activity measured by phosphorylation of the Rb
protein. In a dose-dependent manner, p130 inhibited
cyclin E–Cdk2 protein kinase activity (Figure 4b). Simi-
larly, recombinant p130 coupled to glutathione-S-trans-
ferase (GST) purified from Escherichia coli inhibited cyclin
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Table 1
Cell cycle analysis of cyclin E overexpressors.
% Flow cytometry profile
Cell genotypes % Serum G1 S phase G2/M
p27+/+ 10 64.2 19.6 16.1
0.1 70.6 6.2 23.1
p27–/– 10 60.6 24.6 23.1
0.1 86.9 5.3 7.6
p21–/–p27–/– 10 43.7 41.9 14.2
0.1 53.6 30.5 15.8
Figure 4
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The p130 protein binds to and inactivates cyclin E–Cdk2 complexes in
vivo and in vitro. (a) Proliferating (high serum, Hi) p27+/+ and p27–/–
MEFs were placed in 0.1% serum for 24 h (low serum, Lo); p130
western blots were then performed on whole-cell extracts (top) and
cyclin E immunoprecipitates (bottom). (b) Insect cells were infected
with equal amounts of human cyclin E and Cdk2 virus and at the
indicated multiplicity of infection (m.o.i.) for a p130-expressing virus
(top). Extracts from infected cells were immunoprecipitated using a
human cyclin-E-specific monoclonal antibody and Rb kinase assays
were performed (bottom). Then p130 western blots were performed on
extracts derived from infected cells. Cyclin E and Cdk2 expression, as
well as cyclin E–Cdk2 assembly, were monitored and shown not to be
affected by co-expression of p130 (data not shown). (c) Cyclin E was
immunoprecipitated from insect cells infected with equivalent amounts
of cyclin E and Cdk2 virus. Rb kinase assays were performed on
immunoprecipitated recombinant active cyclin E–Cdk2 complexes that
were incubated with a titration (0, 1.25, 2.5, 3.75 or 5 µg) of bacterially
expressed purified GST alone or GST–p130 (amino acids 1–320).
E–Cdk2 activity in vitro, showing that this was a property
of p130 alone and did not require a p130-associated cellu-
lar protein (Figure 4c). Moreover, this latter experiment
used a portion of p130 (residues 1–320) that does not
contain a Cdk2 phosphorylation site demonstrating that
inhibition of Rb phosphorylation in vitro is not due to sub-
strate competition. 
Deregulation of cyclin E–Cdk2 in p27–/–p130–/– cells
The essential role of p130 in Cdk2 regulation was con-
firmed by examining cyclin E–Cdk2 activity in MEFs
lacking both p27 and p130. When compared with control
MEFs harvested from littermates that were heterozygous
at both loci (p27+/–p130+/–), the doubly deficient MEFs
(p27–/–p130–/–) expressed equal amounts of cyclin E,
Cdk2, p21, cyclin E–Cdk2 complexes and cyclin E–p21
complexes, either in proliferating or serum-starved cells
(Figure 5a). Also, there was no evidence for a compen-
satory increase in p107 expression in the p130-null MEFs
(Figure 5a). Cyclin E–Cdk2 kinase activity was downregu-
lated by mitogen starvation in wild type, p27–/– and
p130+/– p27+/– MEFs (Figures 1,5). But, the absence of
both p27 and p130 resulted in cyclin E–Cdk2 kinase activ-
ity becoming mitogen-independent (Figure 5b). 
Regulation of cyclin E–Cdk2 in T lymphocytes
The above results show that p130 can impose mitogen-
dependent regulation of the cyclin E–Cdk2 complex in
the absence of p27. We would therefore predict that in
cell types that normally express very low amounts of p130,
mitogenic regulation of cyclin E–Cdk2 may depend exclu-
sively on p27. More than 98% of T lymphocytes purified
from the spleens of either wild-type or p27–/– mice are qui-
escent, and can be stimulated to re-enter the cell cycle by
a variety of mitogenic stimuli, such as the lectin con-
canavalin A (ConA; Figure 6a). In quiescent T lympho-
cytes, p27 is expressed at high levels, is downregulated by
mitogen stimulation, and the inactive cyclin E–Cdk2 com-
plexes in quiescent cells are quantitatively bound to p27
[59,60]. In quiescent T cells p21 is not expressed, but it is
induced by mitogens and present at high levels in prolifer-
ating cells [60]. Equal amounts of cyclin E and Cdk2 were
expressed in proliferating and quiescent p27+/+ and p27–/–
T cells (Figure 6b). Also, the amount of cyclin E–Cdk2
complexes present in quiescent lymphocytes was equal to
that present in quiescent MEFs, and was not affected by
p27 status (Figure 6c). 
In each of these respects, therefore, T cells and MEFs
appear to be similar. An important difference, however, is
that quiescent T lymphocytes express much lower
amounts of p130 than do MEFs (Figure 6c). This corre-
lates with the observation that cyclin E–Cdk2 complexes
are catalytically inactive when prepared from quiescent
wild-type T cells, but in p27–/– T cells the cyclin E–Cdk2
kinase is equally active whether the cells are quiescent or
proliferating (Figure 6d). Therefore, p27–/– T cells, which
naturally express low amounts of p130, have a defect in
regulation of the cyclin E–Cdk2 complex similar to that
seen in p27–/–p130–/– MEFs. We conclude that the level of
p130 expression determines how effectively a quiescent
cell can compensate for the absence of p27. In p27–/–
MEFs, the amount of p130 is just adequate to regulate the
normal endogenous amount of cyclin E, but in T lympho-
cytes the amount of p130 is so low that in the absence of
p27, cyclin E–Cdk2 is constitutively active.
Discussion
When normal somatic cells are starved of mitogens, the CKI
p27 is induced, both by an increase in its rate of translation
and by a decrease in its rate of proteolysis [61–64]. The end
result is that in a mitogen-starved, quiescent cell almost
every cyclin–Cdk complex is rendered catalytically inactive
through its association with a CKI, primarily p27. Moreover,
forced ectopic expression of p27 blocks cell proliferation
[65–67], and antisense inhibition of p27 expression in
mitogen-starved cells delays both the downregulation of
CDK activity and exit from the cell cycle [43,44]. On the
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Figure 5
Combined deficiency of p27 and p130 results in mitogen-independent
cyclin E–Cdk2 activity. (a) MEFs of the indicated genotypes were
harvested either when proliferating (high serum, Hi) or after serum
starvation (low serum, Lo). Whole-cell extracts were immunoblotted
using antisera against p130, cyclin E (CycE), p107, Cdk2, p27 and
p21. Cyclin E immunoprecipitates were also analyzed for the presence
of associated Cdk2 and p21. (b) Cyclin E immunoprecipitates from the
cell extracts described in (a) were analyzed for associated histone H1
kinase activity.
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basis of these observations, it was concluded that there is a
cause-and- effect relationship among mitogen-dependent
CDK activity, p27 expression and cell proliferation.
The use of primary cells from genetically modified mice
provides a different and perhaps a more critical test of the
role of CKIs in mitogen-dependent CDK regulation. By
using wild-type, p21-deficient, p27-deficient, p130-defi-
cient and doubly deficient cells we have confirmed the
idea that the CKI p27 is a major regulator of CDK activity
in mitogen-starved quiescent cells. This is most clearly
evident in T lymphocytes, where the regulation of cyclin
E–Cdk2 activity by serum mitogens requires p27. In this
regard it is interesting that the thymus is the organ most
dramatically enlarged in p27-null mice. In embryonic
murine fibroblasts the situation is more complex, but the
data still point to p27 as the major regulator of Cdk2 activ-
ity in mitogen-starved normal cells.  In serum-starved
MEFs p27 is induced to high levels and is quantitatively
associated with catalytically inactive cyclin E–Cdk2; but
we show that in MEFs other proteins can compensate for
the absence of p27.
By studying CDK regulation in the absence of p27, we
have discovered a new pathway for mitogen-dependent
CDK regulation. This pathway involves the tight binding
of p130 to cyclin E–Cdk2 complexes, with consequent
inhibition of Cdk2 catalytic activity toward exogenous
substrates. We show not only that cyclin E–Cdk2 com-
plexes prepared from serum-starved p21–/–p27–/– cells are
inactive and quantitatively bound to p130, but also that
p130 can inhibit Cdk2 catalytic activity both in vivo and in
vitro. Most significantly, the cyclin E–Cdk2 complex is
constitutively active and fully mitogen-independent in
MEFs that lack both p27 and p130.
The mechanism of CDK inhibition by p130 remains to be
established. The p130 protein is not simply a competitive
inhibitor of CDK activity, because the amino-terminal
portion of the p130 protein does not contain a CDK phos-
phorylation site but is nevertheless a potent CKI in vitro.
One possibility is that p130 will fit the paradigm of tight
binding CKIs, like p40Sic1 in S. cerevisiae, and the p21/p27
proteins in mammalian cells [46,65,68]. Thus, the confor-
mation of the CDK catalytic site might be altered by p130,
much as in the p27–cyclin A–Cdk2 complex [69]. Indeed,
p130 has the ‘RxL’ (Arg–X–Lys) motif, which is present
in other cyclin-binding proteins and is required for CDK
inhibition by members of the p21/p27 family [15]. It is not
clear, however, whether or not this motif is required for
p130 to inhibit cyclin E–Cdk2 in vitro, because it is absent
from the amino-terminal inhibitory fragment of p130.
Hence, its mode of inhibition may not mimic the one
employed by the p21/p27 proteins.
Compensatory or redundant effects of cell cycle regula-
tors have been seen before, but these have all been
among family members. For instance, upregulation of
the Rb-family member p107 is seen in p130-null T cells
[70]. Mice lacking both p27 and p57 show more severe
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Figure 6
Regulation of cyclin E–Cdk2 in wild-type and
p27–/– T lymphocytes. (a) Flow cytometric
analysis of murine T lymphocytes from wild-
type (+/+) and p27–/– mice that were either
freshly isolated (quiescent, G0) or stimulated
with 10% serum, ConA and phorbol ester
(PMA) for 48 h (Exponential). The proportion
of cells in S–G2/M is indicated as a
percentage. (b) Cyclin E (top) and Cdk2
(bottom) expression was determined by
immunoblotting whole-cell extracts from
freshly isolated quiescent (G0) and
proliferating (Exp) p27–/– and p27+/+
T lymphocytes. (c) Western blots for p130
were performed on extracts from freshly
isolated quiescent wild-type (p27+/+) and
knockout (p27–/–) murine T lymphocytes and
compared to p130 levels in serum-starved
wild-type and p27 knockout MEFs (top). Cdk2
western blots were performed on cyclin E
immunoprecipitates from quiescent T
lymphocytes and serum-starved quiescent
MEFs of the indicated genotypes (bottom).
(d) Quiescent T lymphocytes (G0) and T
lymphocytes that had been stimulated with
10% serum, ConA and PMA for 48 h (Exp)
were harvested and whole-cell extracts
immunoprecipitated with anti-cyclin E
antiserum; histone H1 kinase assays were
then performed.
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proliferative abnormalities in the lens than do mice
lacking either CKI alone [55]. It is remarkable that in the
experiments described here the cell uses p130, a seem-
ingly unrelated protein, to replace p27. Perhaps the most
important question raised by our results, therefore, is
whether or not CDK inhibition is a normal function of
p130. The fact that p130 is normally upregulated after
mitogen starvation suggests that p130 has a physiological
function in non-dividing cells. Does this function solely
involve inhibition of the function of the transcription
factor E2F [57,71], or might p130 also have a normal role
in more directly regulating CDKs? In MEFs, the CDK-
inhibitory role of p130 is subordinate to that of p27,
because when p27 is present very little p130 is bound to
Cdk2. We therefore expect that if p130 normally acts as a
direct CKI this will occur only in quiescent cells that
express limiting amounts of p27, p21 and possibly p57.
Another possibility is that p130 takes over the function of
CDK inhibition only in abnormal situations where bona fide
CDK regulators are absent. Tumor cells represent one
setting, albeit a pathological one, in which p130 may play an
important role in CDK regulation. Many types of human
carcinomas often express low amounts of the p27 protein
and high amounts of G1 cyclins, including cyclins D1 and E
[72]. Moreover, low p27 and high cyclin expression are each
independently predictive of tumor aggression and patient
mortality [73–76]. The fact that these tumors often lack
functional p53, and hence express very low amounts of p21,
places further demands on p130 to act as a CDK regulator.
Indeed, p130 may be one of the final safeguards against
fully mitogen-independent CDK activity, and measuring its
level of expression may provide significant new biological
information about these potentially aggressive tumors.
Conclusions
The normal pathway for downregulating Cdk2 activity
after mitogen starvation of fibroblasts and T lymphocytes
involves inducible binding of the CKI p27 to the cyclin
E–Cdk2 complex. Accordingly, in p27-null T cells the
activity of the cyclin E–Cdk2 complex is mitogen- inde-
pendent. Surprisingly, however, in p27-null fibroblasts a
new pathway can compensate for the absence of p27 and
fully restore mitogen-dependence to Cdk2 activity. This
requires the binding of the Rb-related protein p130 to the
cyclin E–Cdk2 complex and consequent inhibition of
Cdk2 catalytic activity. These observations show that a
completely unrelated protein can perform the function nor-
mally performed by CKIs. In many human tumors CKIs
are not expressed at normal levels, and in this context
CDK regulation by p130 may be biologically important. 
Materials and methods
MEF generation, stable clones, cell culture and transfections
MEFs were generated from 12 day post coitum mouse embryos of
various genotypes. Embryos were harvested, the heads and internal
organs were removed and carcasses were minced using a scalpel in a
petri dish containing fresh medium. The minced embryo was incubated
with trypsin at 37°C for 15 min and then placed in a 6 cm tissue culture
dish containing DMEM supplemented with 10% FBS, 5 mM glutamine
and penicillin/streptomycin. Cells were incubated for 2 days at 37°C
with 5% CO2 and then counted and re-plated at a density of 3 × 105
cells per 6 cm dish. A portion of the primary cells were frozen at 1 × 106
cells per vial and stored at –150°C while others were maintained on a
3T3 protocol where cells were split every 3 days at a density of 3 × 105
into a 6 cm dish. Vials of primary cells were subsequently thawed once
per week, expanded every 3 days and used in experiments. Except for
the stable cyclin-E-overexpressing clones, primary cells of less than six
passages were used in all experiments. Stable cyclin E clones were
established using human cyclin E subcloned into the LXSH vector as
previously described [77]. Cell lines were established by infecting
MEFs of various genotypes that were less than 20 passages in age and
selecting stable cells with 100 µg/ml of hygromycin B. For transient
transfection experiments, cells were plated at 1 × 106 cells per 10 cm
dish and transfected by the calcium phosphate method. Plasmid DNA
(5–10µg) was resuspended in 0.5 ml  122 mM CaCl2 and added drop-
wise to 0.5 ml 2 × HEPES-buffered saline, mixed once and immediately
added dropwise to plates. Cells were incubated overnight in calcium
phosphate and subsequently rinsed once in medium and re-fed with
fresh medium containing 10% FBS (or 0.1% FBS), incubated an addi-
tional 24 h and harvested. For serum-starvation experiments, subconflu-
ent cells plated at a density of 1 × 106 in 10 cm dishes were rinsed
once with serum-free medium and then re-fed with medium containing
0.1% FBS and incubated an additional 24–48 h. Flow cytometry was
performed as previously described [44].
MEFs were produced with targeted disruptions of both p27 and p130
by intercrossing individual knockout strains [50,78]. The p130-deficient
mice were first backcrossed two generations to 129/Sv mice congenic
to the p27-deficient animals. The p27/p130 double nullizygous animals
were viable but infertile, so double nullizygous MEFs were obtained by
intercrossing p27+/–p130–/– animals. Embryos were harvested 12 days
post coitum, were genotyped by PCR as described, and fibroblasts
were cultivated in DMEM + 10% FBS and penicillin/streptomycin on
the 3T3 protocol.
Isolation of T lymphocytes and cell culture
Murine spleens were harvested and a single-cell suspension prepared
by passage through nylon mesh (100 µm). Red cells were depleted
using a whole blood erythrocyte lysis buffer (R&D Systems, Inc., Min-
nesota) and the resultant cells resuspended in 5% complete RPMI
1640. Non-lymphocyte cells were eliminated by density gradient cen-
trifugation through a discontinuous Percoll gradient as previously
described [60] with the following modifications: gradients were made
from 40% to 100% (2 ml each of 40%, 60%, 80%, 90% and 100%)
and the cell interfaces between 80% and 100% were removed,
washed twice with complete RPMI 1640 and passed through a nylon
wool column. Cells washed from the columns were further depleted of
accessory cells by complement lysis utilizing an anti-heat-stable-
antigen antibody and anti-class II MHC antibody (generously provided
M. Allegre, University of Chicago). Cells were > 95% CD3+ by FACS
analysis (data not shown) and failed to respond to concanavalin A (Con
A). For cell culture, freshly isolated mouse T splenocytes were resus-
pended in RPMI–HEPES 1640 medium containing 10% fetal bovine
serum, 2 mM glutamine and 50 µg/ml gentamycin at a density of
1 × 106 cells/ml. Then 2 µg/ml ConA and 2 ng/ml phorbol myristyl
acetate (PMA) were added to the culture media and the cells were
incubated for an additional 48 h. Flow cytometry was performed to
determine the percentage of cells in different phases of the cell cycle.
Antibodies, plasmids and recombinant proteins
Anti-HA-epitope monoclonal antibodies were obtained from Boehringer
Mannheim, anti-human-cyclin E polyclonal antibodies, anti-murine-cyclin E
polyclonal antibodies, anti-Cdk2 polyclonal and anti-p130 polyclonal anti-
bodies were obtained from Santa Cruz. Anti-p21 polyclonal antibodies
170 Current Biology, Vol 9 No 4
were obtained from Pharmingen and anti-p130 monoclonal antibodies
were obtained from Transduction Laboratories. Anti-p27 polyclonal
antibodies were obtained from Santa Cruz and generated in house as
previously described [44]. Cyclin E–LXSH and Myc-tagged cyclin E
plasmids were generated as previously described [77,79]. HA-tagged
Cdk2-AF plasmids, CAK virus comprised of His-tagged cyclin H,
Cdk7 and p36MAT1, and cyclin E and HA-tagged Cdk2 virus were
generously provided by David Morgan (University of California, San
Francisco). The three components of CAK were co-infected into Sf9
insect cells and active recombinant CAK complexes were purified by
nickel chromatography as previously described [80]. By protein deter-
mination, a 1:1:1 molar ratio of the three CAK components was
present in the final purified complexes. CAK activity was verified by
using recombinant carboxy-terminal domain of RNA polymerase II
protein in kinase assays (generously provided by D. Bentley, Amgen
Inc.). Cyclin E and Cdk2 virus were separately infected into Sf9 cells,
extracts were made and combined at a 1:1 ratio to form inactive
recombinant cyclin E–Cdk2 complexes that were used in the CAK
activation experiments. The p130 virus was generated by cloning the
entire p130 cDNA into the 1392 transfer plasmid and construction of
the baculovirus using the Pharmingen BaculoGold system as
described by the manufacturer (Pharmingen). GST and GST–p130
(1–320) bacterial constructs were constructed and purified as previ-
ously described [81].
Western blots, immunoprecipitation and depletions
Cells were lysed in a modified RIPA buffer (1% Triton-X 100, 10%
Glycerol, 0.1% SDS, 0.5% DOC, 20 mM HEPES at pH 7.4, 100 mM
NaCl) containing protease and phosphatase inhibitors (10 µg/ml each
of aprotinin, leupeptin and pepstatin, 50 mM NaF, 1 mM sodium vana-
date). Protein concentrations were determined by Bradford assay, and
50 µg cell extracts were electrophoresed on 12% polyacrylamide gels.
After transferring to PVDF membranes proteins were detected by incu-
bation in appropriate primary antibodies followed by HRP-conjugated
protein A or HRP-conjugated protein A/G (Sigma) and ECL detection
performed as described by the manufacturer (Amersham).
Immunoprecipitation of lysates from cells was performed as follows:
approximately 200 µl cell lysates normalized for protein concentrations
and incubated at 4°C for 1 h with appropriated dilutions of antibodies,
followed by the addition of 50 µl of a 50% slurry of protein
A/G–Sepharose (Pharmacia) suspended in modified RIPA buffer minus
the SDS and DOC. After rotating 30 min at 4°C the beads were pel-
leted and washed four times with modified RIPA buffer (minus SDS
and DOC), then quenched in SDS sample loading buffer and sepa-
rated by SDS–polyacrylamide gel electrophoresis followed by western
transfer where indicated. Histone H1 and Rb kinase assays were per-
formed as previously described [81,82]. Western blots for p130 were
performed using antibody from Transduction Laboratories while p130
immunoprecipitations were performed using p130 antibody from Santa
Cruz. For p27 and p130 depletion analysis, antibody followed by
protein A/G sepharose addition was performed twice followed by a
third incubation of depleted lysates in protein A/G Sepharose alone to
remove any residual antibody. All depleted lysates were normalized for
protein concentration following the depletions and prior to cyclin E
immunoprecipitation analysis. A p130-competing peptide used as
control for ‘mock’ depleted extracts was purchased from Sigma.
Depleted lysates were analyzed by western blots to confirm that either
p27 or p130 was completely depleted from the extracts. In all cyclin E
immunoprecipitations, excess anti-cyclin E antibody was used and it
was confirmed that cyclin E was quantitatively immunoprecipitated from
the cell extracts.
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